

# Florence Nguyen-Khac

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8668748/publications.pdf>

Version: 2024-02-01

73  
papers

3,545  
citations

186209

28  
h-index

138417

58  
g-index

78  
all docs

78  
docs citations

78  
times ranked

5580  
citing authors

#	ARTICLE	IF	CITATIONS
1	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. <i>Cancer Cell</i> , 2011, 20, 25-38.	7.7	792
2	Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients. <i>Cancer Discovery</i> , 2014, 4, 1088-1101.	7.7	213
3	Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). <i>Blood</i> , 2007, 109, 3451-3461.	0.6	188
4	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. <i>Blood</i> , 2019, 133, 1205-1216.	0.6	164
5	Drug-perturbation-based stratification of blood cancer. <i>Journal of Clinical Investigation</i> , 2017, 128, 427-445.	3.9	124
6	Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia. <i>Haematologica</i> , 2013, 98, 649-654.	1.7	119
7	MYC-containing double minutes in hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as the target gene. <i>Human Molecular Genetics</i> , 2006, 15, 933-942.	1.4	116
8	Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: A systematic reappraisal of classic cytogenetic data. <i>American Journal of Hematology</i> , 2014, 89, 249-255.	2.0	113
9	Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. <i>Blood</i> , 2015, 126, 2110-2117.	0.6	94
10	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC13 lymphoC study. <i>American Journal of Hematology</i> , 2015, 90, 197-203.	2.0	84
11	A new recurrent translocation t(11;14)(q24;q32) involving IGH and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. <i>Leukemia</i> , 2010, 24, 1362-1364.	3.3	82
12	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. <i>Blood</i> , 2015, 125, 856-859.	0.6	70
13	Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. <i>Annals of Hematology</i> , 2012, 91, 863-873.	0.8	65
14	CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLC $\beta$ 1 Activation: Evidence from Mice and Humans. <i>PLoS Medicine</i> , 2015, 12, e1001796.	3.9	65
15	Trisomy 4, a new chromosomal abnormality in Waldenström's macroglobulinemia: a study of 39 cases. <i>Leukemia</i> , 2006, 20, 1634-1636.	3.3	64
16	Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. <i>Blood</i> , 2011, 117, 6109-6119.	0.6	62
17	Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages. <i>Leukemia Research</i> , 2010, 34, 63-68.	0.4	61
18	Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. <i>Haematologica</i> , 2016, 101, 959-967.	1.7	57

#	ARTICLE	IF	CITATIONS
19	Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. <i>Leukemia</i> , 2014, 28, 230-233.	3.3	51
20	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013, 98, 1748-1752.	1.7	50
21	The most frequent t(14;19)(q32;q13)-positive B-cell malignancy corresponds to an aggressive subgroup of atypical chronic lymphocytic leukemia. <i>Leukemia</i> , 2008, 22, 2123-2127.	3.3	47
22	EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. <i>Leukemia</i> , 2017, 31, 1547-1554.	3.3	46
23	Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. <i>Leukemia</i> , 2010, 24, 201-203.	3.3	43
24	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. <i>Haematologica</i> , 2020, 106, 87-97.	1.7	43
25	Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1. <i>Leukemia</i> , 2017, 31, 1625-1629.	3.3	38
26	Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. <i>Blood</i> , 2010, 116, 4588-4590.	0.6	36
27	Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. <i>Haematologica</i> , 2016, 101, e299-e302.	1.7	35
28	Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells. <i>Blood</i> , 2010, 116, 239-249.	0.6	31
29	A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation. <i>Cancer Discovery</i> , 2019, 9, 796-811.	7.7	30
30	High frequency of clonal hematopoiesis in Erdheim-Chester disease. <i>Blood</i> , 2021, 137, 485-492.	0.6	30
31	Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies. <i>Leukemia</i> , 2012, 26, 2027-2031.	3.3	27
32	14q deletions are associated with trisomy 12, <i>NOTCH1</i> mutations and unmutated <i>IGHV</i> genes in chronic lymphocytic leukemia and small lymphocytic lymphoma. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 657-666.	1.5	25
33	<i>IGHV</i> gene mutational status and <i>LPL/ADAM29</i> gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. <i>Annals of Hematology</i> , 2009, 88, 1215-1221.	0.8	23
34	Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. <i>Lancet Haematology</i> , 2018, 5, e82-e94.	2.2	23
35	Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. <i>Annals of Hematology</i> , 2021, 100, 987-993.	0.8	23
36	Sex chromosome loss may represent a disease-associated clonal population in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 240-247.	1.5	22

#	ARTICLE	IF	CITATIONS
37	Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact. <i>American Journal of Hematology</i> , 2021, 96, 1569-1579.	2.0	22
38	Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e470-e479.	2.2	20
39	The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. <i>American Journal of Hematology</i> , 2020, 95, 1361-1367.	2.0	20
40	Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 533-540.	1.5	18
41	Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. <i>Blood</i> , 2019, 134, 1821-1831.	0.6	18
42	Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2022, 107, 593-603.	1.7	18
43	No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. <i>Haematologica</i> , 2018, 103, e158-e161.	1.7	16
44	Chromosomal abnormalities in transformed Philadelphia-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 919-927.	1.5	15
45	Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males. <i>BMC Medical Genomics</i> , 2010, 3, 53.	0.7	15
46	Specific chromosomal IG translocations have different prognoses in chronic lymphocytic leukemia. <i>American Journal of Blood Research</i> , 2011, 1, 13-21.	0.6	15
47	Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. <i>Haematologica</i> , 2019, 104, 1150-1155.	1.7	14
48	The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH). <i>Leukemia</i> , 2022, 36, 1451-1466.	3.3	14
49	Functional assessment of p53 in chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2011, 1, e5-e5.	2.8	13
50	Chronic lymphocytic leukemia: Time to go past genomics?. <i>American Journal of Hematology</i> , 2016, 91, 518-528.	2.0	13
51	Double-hit chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain. <i>American Journal of Hematology</i> , 2018, 93, 375-382.	2.0	13
52	Chronic lymphocytic leukaemia genomics and the precision medicine era. <i>British Journal of Haematology</i> , 2017, 178, 852-870.	1.2	12
53	Trisomy 4 associated with double minute chromosomes and MYC amplification in acute myeloblastic leukemia. <i>Annales De G�n�tique</i> , 2004, 47, 423-427.	0.4	11
54	Aberrant telomere structure is characteristic of resistant chronic lymphocytic leukaemia cells. <i>Leukemia</i> , 2010, 24, 246-251.	3.3	11

#	ARTICLE	IF	CITATIONS
55	Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance. <i>Blood Advances</i> , 2019, 3, 2920-2933.	2.5	11
56	Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2019, 8, 3131-3141.	1.3	10
57	Identification of two DNA methylation subtypes of Waldenström's macroglobulinemia with plasma and memory B cell features. <i>Blood</i> , 2020, 136, 585-595.	0.6	10
58	A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. <i>Blood</i> , 2021, 137, 1019-1023.	0.6	10
59	Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin. <i>Cancer Genetics and Cytogenetics</i> , 2005, 159, 74-78.	1.0	8
60	Clinical and biological features of B-cell neoplasms with <i>CDK6</i> translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and <i>TP53</i> abnormalities. <i>British Journal of Haematology</i> , 2021, 193, 72-82.	1.2	8
61	Transcriptional activation of the cardiac homeobox gene <i>CSX1/NKX2-5</i> in a B-cell chronic lymphoproliferative disorder. <i>Haematologica</i> , 2008, 93, 1081-1085.	1.7	7
62	<i>Nfkb</i> deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice. <i>Blood Cancer Journal</i> , 2020, 10, 38.	2.8	7
63	Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization. <i>American Journal of Hematology</i> , 2021, 96, E311-E314.	2.0	7
64	Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH). <i>Annales De Biologie Clinique</i> , 2016, 74, 561-567.	0.2	6
65	<i>LHX2</i> deregulation by juxtaposition with the IGH locus in a pediatric case of chronic myeloid leukemia in B-cell lymphoid blast crisis. <i>Leukemia Research</i> , 2012, 36, e195-e198.	0.4	5
66	Recommendations for cytogenomic analysis of hematologic malignancies: comments from the Francophone Group of Hematological Cytogenetics (GFCH). <i>Leukemia</i> , 2020, 34, 1711-1713.	3.3	5
67	Concomitant telomere shortening, acquisition of multiple chromosomal aberrations and in vitro resistance to apoptosis in a single case of progressive CLL. <i>Leukemia Research</i> , 2011, 35, e37-e40.	0.4	3
68	“Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes. <i>Frontiers in Oncology</i> , 2021, 11, 826245.	1.3	3
69	Absence of microsatellite instability in human chronic lymphocytic leukaemia B cells. <i>Leukemia</i> , 2008, 22, 186-189.	3.3	2
70	Isolated isochromosomes <i>i(X)(p10)</i> and <i>idic(X)(q13)</i> are associated with myeloid malignancies and dysplastic features. <i>American Journal of Hematology</i> , 2019, 94, E285-E288.	2.0	2
71	Acquisition of <i>TCF3</i> and <i>CCND3</i> Mutations and Transformation to Burkitt Lymphoma in a Case of B-Cell Prolymphocytic Leukemia. <i>HemaSphere</i> , 2021, 5, e563.	1.2	2
72	Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network. <i>Biomolecules</i> , 2022, 12, 901.	1.8	2

#	ARTICLE	IF	CITATIONS
73	Intracranial Cell Lymphomas That Mimic Meningiomas: Case Report To Understand Complex Genetic, Radiologic, and Histopathologic Entities. <i>World Neurosurgery</i> , 2019, 125, 339-342.	0.7	1